Color Code
Light Blue

Newborn Screening Test for Spinal Muscular Atrophy

1026
Rachna Chandora, MPH
Chronic Disease & Birth Defects
Maternal and Child Health
Newborn screening
Off
Newborn Screening Test for Spinal Muscular Atrophy
CDC's Division of Laboratory Sciences
Biogen MA Inc.
United States of America
/give
To facilitate collaborative development of a newborn bloodspot screening test to detect the genetic lesions that cause spinal muscular atrophy. The test will be designed to use in public health newborn screening laboratories.
Birth Defects

Preventing Mother-to-Child Transmission of HIV and HBV

679
Chronic Disease & Birth Defects
Maternal and Child Health
pregnant woman
Off
Preventing Mother-to-Child Transmission of HIV
CDC's National Center for Chronic Disease Prevention and Health Promotion
Gilead Sciences, Inc.
China
/give
To help CDC increase understanding of the effectiveness of using maternal tenofovir containing combination drug during the second and third trimesters of pregnancy for the prevention of mother-to-child transmission of HIV and HBV in co-infected mothers.
Gilead Sciences, Inc.
CDC's National Center for Chronic Disease Prevention and Health Promotion
HIV
Pregnancy

Building U.S. Capacity to Review and Prevent Maternal Deaths

According to CDC, about 700 women die each year in the United States as a result of pregnancy or delivery complications.

Related Media Articles

Building U.S. Capacity to Review and Prevent Maternal Deaths promotes the maternal mortality review process as the best way to understand why maternal mortality in the United States is increasing, and identify interventions to prevent maternal deaths. It supports essential review functions and enables data to be combined across jurisdictions for national learning, which was not previously possible. The initiative is a collaboration between the CDC Foundation, the Centers for Disease Control and Prevention (CDC) and the Association of Maternal and Child Health Programs (AMCHP). Funding for the collaboration was provided through an award agreement with Merck on behalf of its Merck for Mothers program.

Learn more about this program in the new 2018 Report From Nine Maternal Mortality Review Committees. The data used in this report is made possible by a partnership with nine states: Colorado, Delaware, Georgia, Hawaii, Illinois, North Carolina, Ohio, South Carolina, and Utah, who have been supporting the development of the Maternal Mortality Review Information Application (MMRIA). The 2017 Report from Maternal Mortality Review Committees: A View Into Their Critical Role is also available. Additional resources that support maternal mortality review committees are available at the Review to Action website.

RTA logo

                    MMRIA

 

896
Chronic Disease & Birth Defects
Women's Health
pregnant woman
Off
Building U.S. Capacity to Review and Prevent Maternal Deaths
CDC's National Center for Chronic Disease Prevention and Health Promotion
United States of America
/give
To increase the United States' capacity to use data for preventing maternal mortality.
Merck for Mothers
CDC's National Center on Birth Defects and Developmental Disabilities
Maternal Health

Sickle Cell Data Collection (SCDC) Program

855
Rebecca Cook, MPH
Chronic Disease & Birth Defects
Population Health
sickle cell disease
Off
Sickle Cell Data Collection (SCDC) Program
California and Georgia, USA
CDC's National Center on Birth Defects and Developmental Disabilities
Pfizer Inc.
Sanofi
Global Blood Therapeutics, Inc.
Doris Duke Charitable Foundation
United States of America
/give
To build the framework for collecting data about individuals in the United States with sickle cell disease in order to monitor their health outcomes, evaluate current systems of care, and inform the development of a comprehensive care model to meet the needs of these individuals throughout their life.
Biogen; Pfizer Inc.; Global Blood Therapeutics
CDC’s National Center on Birth Defects and Developmental Disabilities
Hide Title
Off
Hide Teaser
Off
Hide Partners
Off
Hide Program Location
Off
Hide Program Initiative
Off
Hide Program Type
Off
Hide Tags
Off
Birth Defects

Healthy People Law and Health Policy Project

994
Sekou Sidibe, MPH
Chronic Disease & Birth Defects
Population Health
chronic
Off
Healthy People Law and Health Policy Project
CDC's National Center for Chronic Disease Prevention and Health Promotion
Robert Wood Johnson Foundation
United States of America
/give
To collaborate with the Healthy People Initiative (a science-based, 10-year national objective for improving the health of Americans) to demonstrate the value of legal and policy interventions in improving Americans’ health.
Robert Wood Johnson Foundation
CDC's National Center for Chronic Disease Prevention and Health Promotion

Hormone Laboratory Collaborations

524
Chronic Disease & Birth Defects
Laboratory Research and Analysis
Lab
Off
Hormone Laboratory Collaborations
CDC's Division of Laboratory Sciences
Abbott Laboratories
American Chemistry Council
American University of Beirut
Ann & Robert H. Lurie Children's Hospital of Chicago
ARUP Laboratories
Beckman Coulter, Inc.
Bio-Rad Laboratories, Inc.
BMH Holdings LLC
Covance
DiaSorin Inc.
DIAsource Immunoassays
Douglass Hanly Moir Pathology
Endoceutics, Inc.
Eurofins Biomnis
Euroimmun Medizinische Labordiagnostika AG
Fujirebio Diagnostics, Inc
Fujirebio Inc.
Health Canada
Immunodiagnostic Sytems Inc.
Immunotech S.A.S.
Laboratory Corporation of America Holdings
Los Angeles Biomedical Research Institute (formerly LA BioMed)
Microgenics Corporation
New England Research Institutes, Inc.
Pathology Associates Medical Laboratories
Quest Diagnostics
ReproSource
Roche Diagnostics Corporation
Social & Scientific Systems, Inc.
Tosoh Bioscience, Inc.
Tricore Reference Laboratories
University College Cork
University of Helsinki
VU University Medical Center Amsterdam
ZRT Laboratory, LLC
multiple donors
United States of America
/give
To help CDC provide reference and quality control materials for laboratory collaboration, including collaborations for the Hormone Measurement Standardization program.
AB SCIEX; Abbott Laboratories; American University of Beirut; Ann & Robert H. Lurie Children's Hospital of Chicago; ARUP Laboratories; Beckman Coulter, Inc.; Bio-Rad Laboratories, Inc.; BMH Holdings (TMS BioScience Labs); Covance; DiaSorin Inc.; DIAsource Immunoassays; Douglass Hanly Moir Pathology; Endoceutics, Inc.; Euroimmun Medizinische Labordiagnostika AG; Fujirebio Diagnostics, Inc; Fujirebio Inc.; Health Canada; Immunodiagnostic Systems Inc.; Immunotech S.A.S. (Beckman Coulter, Inc); Laboratory Corporation of America Holdings; Los Angeles Biomedical Research Institute; Microgenics Corporation (Thermo Fisher Scientific, Inc.); New England Research Institutes, Inc.; Harvard University (Partners HealthCare System, Inc.); Pathology Associates Medical Laboratories; Quest Diagnostics; Reprosource Fertility Diagnostics; Roche Diagnostics Corporation; Sahlgrenska University Hospital; Siemens; Social & Scientific Systems, Inc.; Tosoh Bioscience, Inc.; Tricore Reference Laboratories; University College Cork; University of Helsinki; VU University Medical Center Amsterdam; ZRT Laboratory; multiple donors
CDC's Division of Laboratory Sciences
Subscribe to Chronic Disease & Birth Defects